Intensity Therapeutics Inc. (NASDAQ:INTS) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have earned a consensus rating of “Moderate Buy” from the four ratings firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $37.50.

A number of research analysts have recently commented on INTS shares. Benchmark reiterated a “speculative buy” rating on shares of Intensity Therapeutics in a report on Wednesday, May 20th. Weiss Ratings downgraded shares of Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. Wall Street Zen raised shares of Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. Finally, Freedom Capital upgraded shares of Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Monday, March 30th.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its position in shares of Intensity Therapeutics by 77.8% during the fourth quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock valued at $189,000 after buying an additional 201,357 shares during the last quarter. Mesirow Financial Investment Management Inc. grew its position in Intensity Therapeutics by 25.5% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock worth $103,000 after buying an additional 51,000 shares in the last quarter. Legacy Advisors LLC bought a new position in Intensity Therapeutics during the fourth quarter valued at about $63,000. State Street Corp increased its stake in Intensity Therapeutics by 839.3% during the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after acquiring an additional 121,700 shares during the period. Finally, Corient Private Wealth LLC acquired a new position in Intensity Therapeutics in the 4th quarter valued at approximately $41,000. Institutional investors own 3.74% of the company’s stock.

Intensity Therapeutics Price Performance

NASDAQ INTS opened at $4.90 on Friday. Intensity Therapeutics has a twelve month low of $3.51 and a twelve month high of $43.50. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.86 and a current ratio of 4.86. The stock has a market capitalization of $13.23 million, a PE ratio of -0.86 and a beta of 2.78. The stock has a 50-day simple moving average of $4.35 and a 200 day simple moving average of $6.37.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Thursday, May 7th. The company reported ($0.96) earnings per share for the quarter, beating the consensus estimate of ($1.08) by $0.12. Research analysts anticipate that Intensity Therapeutics will post -2.7 EPS for the current year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.